Research Article
Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells
Published Online:26 Apr 2011https://doi.org/10.2217/pgs.10.200
Abstract
Aim: To adopt an individualized approach to assess cytarabine (ara-C) hematotoxicity, we studied the relationship between pharmacogenetic variability in the cytidine deaminase gene (CDA) and ara-C toxicity in native peripheral blood mononuclear cells from 100 healthy volunteers. Materials & methods: Peripheral blood mononuclear cells were incubated for 48 h with 3 µM ara-C, and cell viability was analyzed by flow cytometry with and without the addition of an equilibrative nucleoside transporter transport inhibitor. CDA promoter and exonic variants were genotyped to derive haplotypes for the CDA gene. Results: Significant between-subject variability was observed in ara-C toxicity (21-fold with 40.1% coefficient of variation compared with 1.2-fold within-subject variability [9.6% coefficient of variation]). Inhibition of hENT1 reversed ara-C cytotoxicity. The linked CDA promoter variants -451C>T, -92A>G, -31Del and the exonic 79A>C variant were associated with ara-C toxicity (p < 0.05). CDA*2A haplotype was associated with ara-C toxicity (p = 0.03). Conclusion: Genetic polymorphisms within CDA may be risk factors for ara-C-induced hematotoxicity.
Original submitted 6 October 2010; Revision submitted 29 November 2010.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
Bibliography
- 1 Welsh M, Mangravite L, Medina MW et al.: Pharmacogenomic discovery using cell-based models. Pharmacol. Rev.61(4),413–429 (2009).Crossref, Medline, CAS, Google Scholar
- 2 Zhang W, Dolan ME: Use of cell lines in the investigation of pharmacogenetic loci. Curr. Pharm. Des.15(32),3782–3795 (2009).Crossref, Medline, CAS, Google Scholar
- 3 Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood106(4),1154–1163 (2005).Crossref, Medline, CAS, Google Scholar
- 4 Mackey JR, Baldwin SA, Young JD, Cass CE: Nucleoside transport and its significance for anticancer drug resistance. Drug Resist. Updat.1(5),310–324 (1998).Crossref, Medline, CAS, Google Scholar
- 5 Boleti H, Coe IR, Baldwin SA, Young JD, Cass CE: Molecular identification of the equilibrative nbmpr-sensitive (es) nucleoside transporter and demonstration of an equilibrative nbmpr-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology36(9),1167–1179 (1997).Crossref, Medline, CAS, Google Scholar
- 6 Endo Y, Obata T, Murata D et al.: Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides. Cancer Sci.98(10),1633–1637 (2007).Crossref, Medline, CAS, Google Scholar
- 7 Clarke Ml, Damaraju Vl, Zhang J et al.: The role of human nucleoside transporters in cellular uptake of 4´-thio-β-D-arabinofuranosylcytosine and β-D-arabinosylcytosine. Mol. Pharmacol.70(1),303–310 (2006).Crossref, Medline, CAS, Google Scholar
- 8 Coleman CN, Stoller RG, Drake JC, Chabner BA: Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood46(5),791–803 (1975).Crossref, Medline, CAS, Google Scholar
- 9 Plunkett W, Liliemark JO, Estey E, Keating MJ: Saturation of ara-ctp accumulation during high-dose ara-c therapy: pharmacologic rationale for intermediate-dose ara-c. Semin. Oncol.14(2 Suppl. 1),159–166 (1987).Medline, CAS, Google Scholar
- 10 Laliberte J, Momparler Rl: Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res.54(20),5401–5407 (1994).Medline, CAS, Google Scholar
- 11 Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE: Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet.119(3),276–283 (2006).▪ First report of functional variants in the CDA promoter region.Crossref, Medline, CAS, Google Scholar
- 12 Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J: Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp. Hematol.26(5),421–425 (1998).▪ First in vitro study reporting a reduced CDA activity for the C allele of the CDA 79A>C variant.Medline, CAS, Google Scholar
- 13 Gilbert JA, Salavaggione OE, Ji Y et al.: Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res.12(6),1794–1803 (2006).▪▪ First comprehensive assessment of CDA haplotypes in multiple ethnic panels. Provides nomenclature for common CDA haplotypes.Crossref, Medline, CAS, Google Scholar
- 14 Osato DH, Huang CC, Kawamoto M et al.: Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ent1. Pharmacogenetics13(5),297–301 (2003).▪ Comprehensive identification and functional analysis of hENT1 genetic variants.Crossref, Medline, CAS, Google Scholar
- 15 Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE: Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet. Genomics16(5),315–320 (2006).Crossref, Medline, CAS, Google Scholar
- 16 Lamba JK, Crews K, Pounds S et al.: Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J. Pharmacol. Exp. Ther.323(3),935–945 (2007).▪ First report on polymorphisms in the deoxycytidine kinase gene.Crossref, Medline, CAS, Google Scholar
- 17 Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH: Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur. J. Clin. Pharmacol.62(8),681–684 (2006).Crossref, Medline, CAS, Google Scholar
- 18 Kessel D, Hall TC, Rosenthal D: Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro. Cancer Res.29(2),459–463 (1969).Medline, CAS, Google Scholar
- 19 Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of ld and haplotype maps. Bioinformatics21(2),263–265 (2005).Crossref, Medline, CAS, Google Scholar
- 20 Lewontin RC: The interaction of selection and linkage. II. Optimum models. Genetics50,757–782 (1964).Crossref, Medline, CAS, Google Scholar
- 21 Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet.73(5),1162–1169 (2003).Crossref, Medline, CAS, Google Scholar
- 22 Bhatla D, Gerbing RB, Alonzo TA et al.: Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol.144(3),388–394 (2009).▪ First study to report the association of CDA genetic variation with the rate of cytarabine-induced toxicity.Crossref, Medline, CAS, Google Scholar
- 23 Mahlknecht U, Dransfeld CL, Bulut N et al.: Snp analyses in cytarabine metabolizing enzymes in aml patients and their impact on treatment response and patient survival: identification of CDA SNP C-451t as an independent prognostic parameter for survival. Leukemia23(10),1929–1932 (2009).Crossref, Medline, CAS, Google Scholar
- 24 Sarkar M, Han T, Damaraju V, Carpenter P, Cass CE, Agarwal RP: Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Biochem. Pharmacol.70(3),426–432 (2005).Crossref, Medline, CAS, Google Scholar
- 25 Mata JF, Scrideli CA, Queiroz RP et al.: Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia. Braz. J. Med. Biol. Res.39(11),1417–1423 (2006).Crossref, Medline, CAS, Google Scholar
- 26 Hubeek I, Stam RW, Peters GJ et al.: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer93(12),1388–1394 (2005).Crossref, Medline, CAS, Google Scholar
- 27 Stam RW, Den Boer Ml, Meijerink JP et al.: Differential mRNA expression of ara-c-metabolizing enzymes explains ara-c sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood101(4),1270–1276 (2003).Crossref, Medline, CAS, Google Scholar
- 28 Galmarini CM, Thomas X, Calvo F et al.: In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol.117(4),860–868 (2002).Crossref, Medline, CAS, Google Scholar
- 29 Jordheim LP, Nguyen-Dumont T, Thomas X, Dumontet C, Tavtigian SV: Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53. Drug Metab. Dispos.36(12),2419–2423 (2008).Crossref, Medline, CAS, Google Scholar
- 30 Lamba JK: Genetic factors influencing cytarabine therapy. Pharmacogenomics10(10),1657–1674 (2009).Link, CAS, Google Scholar
- 31 Hartford CM, Duan S, Delaney SM et al.: Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood113(10),2145–2153 (2009).Crossref, Medline, CAS, Google Scholar
- 32 Li L, Fridley Bl, Kalari K et al.: Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res.68(17),7050–7058 (2009).▪▪ First study utilizing lymphoblastoid cells as a model to study impact of genetic factors on cytarabine cytotoxicity.Crossref, Google Scholar
- 33 Claes B, Buysschaert I, Lambrechts D: Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. Heredity105(1),152–160 (2010).Crossref, Medline, CAS, Google Scholar
- 34 Turan N, Katari S, Coutifaris C, Sapienza C: Explaining inter-individual variability in phenotype: is epigenetics up to the challenge? Epigenetics5(1),16–19 (2010).Crossref, Medline, CAS, Google Scholar
- 35 Bryant PA, Smyth GK, Robins-Browne R, Curtis N: Detection of gene expression in an individual cell type within a cell mixture using microarray analysis. PLoS ONE4(2),e4427 (2009).Crossref, Medline, Google Scholar
